IX1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Diagnostics GrowthStrong recurring CAG Diagnostics growth shows that IDEXX benefits from repeat testing and consumable usage across its installed base. Continued organic expansion, including net price realization, supports customer retention, revenue visibility, and durable earnings growth over the next several quarters.
Margin ExpansionImproving operating and gross margins indicate that IDEXX is converting revenue growth into greater profitability through pricing, scale, and cost control. Sustained margin expansion can strengthen earnings growth, increase internal funding capacity, and reinforce the economics of its diagnostics platform.
Strong Free Cash FlowRobust free cash flow and healthy conversion from net income demonstrate strong earnings quality and provide financial flexibility. This cash generation supports investment in innovation, ongoing capital returns, and balance-sheet resilience while reducing reliance on external financing.
Bears Say
U.S. Visit PressureLower U.S. clinical and wellness visits can constrain testing volumes because veterinary diagnostics are linked to patient encounters. Continued discretionary spending pressure and slower puppy adoption may weigh on clinic activity, limiting volume-led growth even as IDEXX gains share.
Foreign-Exchange HeadwindsCurrency exposure creates an ongoing translation headwind for reported revenue and earnings, particularly across IDEXX’s international operations. Although organic performance remains positive, further dollar strength could reduce reported growth, EPS, and the pace of margin improvement.
Growth NormalizationA moderating revenue-growth rate suggests IDEXX is moving into a more mature phase, reducing the contribution from rapid top-line expansion. Slower growth can limit operating leverage and make continued execution, innovation, and recurring customer adoption more important to future earnings.
Idexx Laboratories News
IX1 FAQ
What was Idexx Laboratories’s price range in the past 12 months?
Currently, no data Available
What is Idexx Laboratories’s market cap?
Idexx Laboratories’s market cap is CHF34.39B.
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s upcoming earnings report date is Nov 02, 2026 which is in 20 days.
How were Idexx Laboratories’s earnings last quarter?
Idexx Laboratories released its earnings results on Aug 04, 2026. The company reported CHF3.558 earnings per share for the quarter, beating the consensus estimate of CHF3.286 by CHF0.272.
Is Idexx Laboratories overvalued?
According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued.
Does Idexx Laboratories pay dividends?
Idexx Laboratories does not currently pay dividends.
What is Idexx Laboratories’s EPS estimate?
Idexx Laboratories’s EPS estimate is 3.09.
How many shares outstanding does Idexx Laboratories have?
Idexx Laboratories has 78,781,110 shares outstanding.
What happened to Idexx Laboratories’s price movement after its last earnings report?
Idexx Laboratories reported an EPS of CHF3.558 in its last earnings report, beating expectations of CHF3.286. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Idexx Laboratories?
Currently, no hedge funds are holding shares in CH:IX1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Idexx Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF579.98 (― Upside)
CHF579.98 (― Upside)
Blogger Sentiment
Bullish
CH:IX1 Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth CHF976.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.96%
12-Months-Change
Fundamentals
Return on Equity
71.96%
Trailing 12-Months
Asset Growth
3.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Idexx Laboratories
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
IX1 Company Deck
IX1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly constructive operational and financial picture: solid organic revenue growth (~9% Q2), recurring CAG Diagnostics strength, robust margin and EPS expansion, strong free cash flow and aggressive capital returns, plus clear product and innovation momentum (inVue Dx, Cancer Dx, Catalyst SDMA). Offsetting items include continued pressure on U.S. clinic and wellness visits, a Q2 instrument revenue lap effect, foreign-exchange headwinds, and planned incremental investments that will temper near-term margin gains. Overall, the positive drivers — durable recurring revenue expansion, margin gains, cash generation, and multiple innovation milestones — materially outweigh the cited headwinds.View all CH:IX1 earnings summariesIX1 Revenue Breakdown
91.86% CAG
4.67% Water
3.06% LPD
0.41% Other

IX1 Stock 12 Month Forecast
All Analysts
Top Analysts











